In contrast, both CDK4/6 knockdown and palbociclib enhanced glucose metabolism in HCT116 colorectal cancer cells [18], and elevated glycolysis was also observed in pancreatic cancer cells following CDK4/6 inhibition via palbociclib, abemaciclib and ribociclib [19]. The gene discussed is CDK4; the disease is familial pancreatic carcinoma.